Form 4: Cadrenal Therapeutics Insider Sells Shares

Quang X. Pham, Director and Officer of Cadrenal Therapeutics, Inc., reported the sale of common stock totaling 11,444 shares on June 22-23, 2026, under a Rule 10b5-1 trading plan.

Summary

• Quang X. Pham, who holds positions as Director, 10% Owner, and Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc., has reported transactions involving the sale of company common stock.
• These sales occurred on June 22, 2026, and June 23, 2026.
• A total of 9,167 shares were sold on June 22, 2026, at a weighted average price of $3.55.
• An additional 2,277 shares were sold on June 23, 2026, at a weighted average price of $3.20.
• These transactions were conducted under a Rule 10b5-1 trading arrangement established on September 25, 2025.
• Following these sales, Mr. Pham's direct beneficial ownership of common stock is 117,145 shares.
• Additionally, Mr. Pham beneficially owns 200,000 shares indirectly through The PVBQ Living Trust, where he serves as Trustee and has sole voting and dispositive power, with his child as the sole beneficiary.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the significant sale of shares by a key executive, despite the use of a Rule 10b5-1 plan.

Positives

• The sales were executed under a pre-arranged Rule 10b5-1 trading plan, which is designed to comply with insider trading regulations and can provide an affirmative defense against allegations of insider trading.
• Mr. Pham retains significant beneficial ownership, with 117,145 shares directly and 200,000 shares indirectly.

Negatives

• The reporting person, a key executive and director, has sold a notable number of shares.
• The sales represent a reduction in direct beneficial ownership by a significant insider.

Risks

• Potential for negative market perception due to insider selling, which could lead to downward pressure on the stock price.
• The Rule 10b5-1 plan, while a defense, still involves the actual disposal of shares by a key executive.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it solely reports on past transactions.

Management Comments

• The sales were made in accordance with a Rule 10b5-1 trading arrangement.
• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price upon request.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, can sometimes be interpreted negatively by the market, regardless of the underlying strategic reasons. This is particularly relevant in the biotechnology sector where stock performance can be highly sensitive to executive confidence.

Related Party Transactions

• The sale of shares by Quang X. Pham, who is an officer and director, could be considered a related party transaction in a broader sense, though this filing specifically details his personal stock sales under a pre-defined plan.

Stakeholder Impact

• Shareholders may view insider selling with concern, potentially impacting stock price.
• Employees may interpret the sales as a signal of management's confidence (or lack thereof) in the company's future prospects.
• Creditors and suppliers are unlikely to be directly impacted by this specific filing.

Next Steps

• The reporting person may continue to execute trades under the Rule 10b5-1 plan if it remains active.
• The company's stock performance will be subject to market reaction to this insider selling.

Key Dates

Recommendation

While insider selling can be a negative signal, the transactions were conducted under a Rule 10b5-1 plan, suggesting a pre-determined strategy rather than a reaction to non-public information. The reporting person retains substantial indirect ownership. Therefore, a 'hold' recommendation is appropriate, pending further company performance and strategic updates.

Keywords

Cadrenal Therapeutics, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Beneficial Ownership, Quang X. Pham, Director, CEO, CVKD